[Blinatumomab (B-ALL, high-risk first relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018015951
German
Original Title: Blinatumomab (B-ALL, Hochrisiko-Erstrezidiv, Kinder und Jugendliche ≥ 1 Monat)
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a26-60.html
Year Published: 2026
URL for published report: https://www.iqwig.de/download/a26-60_blinatumomab_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A26-60
MeSH Terms
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Child
  • Adolescent
  • Antineoplastic Agents
  • Antibodies, Bispecific
  • Infant
Keywords
  • Blinatumomab
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Child
  • Adolescent
  • Benefit Assessment
  • NCT02393859
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.